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Abstract: The cellular delivery of cell-impermeable and water-insoluble molecules remains an ongoing
challenge to overcome. Previously, we reported amphipathic cyclic peptides c[WR]4 and c[WR]5
consisting of alternate arginine and tryptophan residues as nuclear-targeting molecular transporters.
These peptides contain an optimal balance of positive charge and hydrophobicity, which is required
for interactions with the phospholipid bilayer to facilitate their application as a drug delivery
system. To further optimize them, we synthesized and evaluated a multivalent tricyclic peptide as an
efficient molecular transporter. The monomeric cyclic peptide building blocks were synthesized using
Fmoc/tBu solid-phase chemistry and cyclization in the solution and conjugated with each other through
an amide bond to afford the tricyclic peptide, which demonstrated modest antibacterial activity against
methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Pseudomonas aeruginosa,
and Escherichia coli (E. coli) with a minimum inhibitory concentration (MIC) of 64–128 µg/mL.
The tricyclic peptide was found to be nontoxic up to 30µM in the breast cancer cell lines (MDA-MB-231).
The presence of tricyclic peptide enhanced cellular uptakes of fluorescently-labeled phosphopeptide
(F’-GpYEEI, 18-fold), anti-HIV drugs (lamivudine (F’-3TC), emtricitabine (F’-FTC), and stavudine
(F’-d4T), 1.7–12-fold), and siRNA (3.3-fold) in the MDA-MB-231 cell lines.
Keywords: antibacterial activity; cell-penetrating peptide; cyclic peptide; tricyclic; cellular uptake;
cytotoxicity; drug delivery; MDA-MB-231; phosphopeptide; siRNA
1. Introduction
Multivalency is a pervasive phenomenon that has attracted attention for therapeutic development
with the examples of multivalent aptamers, a multivalent effect in glycosidase inhibition, and many
more [1–4]. Multivalent binding plays an essential role in signal transduction and self-organization
in biological systems and is mainly based on the multiple simultaneous molecular recognition
processes [5,6]. Nature’s one good example of multivalency is proteins forming multimeric architectures
in the form of receptors or enzymes that contain several recognition sites.
Peptide-based multivalent interactions at interfaces of a biological system are of great importance.
For example, the multivalency of carefully designed supramolecular peptide ligands was utilized
in enhancing binding interaction with β-cyclodextrin (β-CD) to study host–guest relationships [7].
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In another approach, multivalency was achieved using self-assembly of a coil/fiber-forming peptide
to study the binding interaction with antibody and carbohydrate-binding motifs [8]. Henning et al.
observed tenfold enhanced binding affinity of the lead peptide by generating multivalent property
using dendritic polymer containing polyethylene glycol (PEG) against one of WW binding domains of
FBP21 protein, which is important for splicing of pre-mRNA in the nucleus [9]. Using a very similar
dendritic polymer with PEG scaffold, Lauster et al. developed multivalent peptide–nanoparticle
conjugates for targeting spike protein on the influenza virus [10]. Multivalency is an important aspect,
which needs more exploitation for other applications, such as molecular transporter and drug delivery,
especially using peptide-based transporters.
Peptides are extensively used in drug delivery of a diverse class of therapeutics across phospholipid
bilayer due to their cationic and amphipathic nature. Because of enhanced selectivity and metabolic
stability of cyclic peptides, they are preferred to their counterpart linear peptides for drug delivery
applications [11]. Besides several other classes of cyclic peptides [12–15], developed cyclic peptide
c[WR]4 and c[WR]5 (Figure 1) [16] containing naturally occurring alternate L-tryptophan (W) and
L-arginine (R) amino acid demonstrated a prominent application for the delivery of negatively-charged
phosphopeptide, antiviral drugs, and anticancer drugs (doxorubicin, paclitaxel, and camptothecin)
and were used as a capping agent to the selenium and gold nanoparticles for better drug delivery
applications [17–22]. These series of cyclic peptides showed nuclear localization, low cytotoxicity,
biodegradable property, and endocytosis-independent cellular uptake [13]. Thus, these properties
made them excellent candidates as molecular transporters.
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(0.1% trifluoracetic acid (TFA)) and water (0.1% TFA) over 60 min. Peptides were characterized for 
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Figure 1. The chemical structures of previously reported mon - and bicyclic peptides, c[WR]5, c[WR]4 [16],
c R4W4] [23], and (c[W5G]-(triazole)-c[KR5], and c[W5E]-(β-Ala)-c[KR5]) [22].
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We also discovered that a block of four subsequent tryptophan and positive-charged arginine
residues generated amphipathic antibacterial peptide c[R4W4], which demonstrated minimum
inhibitory concentration (MIC) of 4 µg/mL against methicillin-resistant Staphylococcus aureus (MRSA)
and 16 µg/mL against E. coli [23]. Furthermore, the structure-activity relationship showed the
importance of tryptophan and arginine residues in this pattern for antibacterial activity [24].
Furthermore, to gain a deep understanding of c[WR]5 series of peptide for their molecular
transporter property, we developed a series of bicyclic peptides (c[W5G]-(triazole)-c[KR5] and
c[W5E]-(β-Ala)-c[KR5]) containing two cyclic peptides (c[W5G] and c[KR5]) joined through a flexible
amide or nonflexible triazole linker (Figure 1) and evaluated the delivery of a negatively-charged
phosphopeptide [22]. It was found that bicyclic peptide containing amide linkage c[W5E]-(β-Ala)-c[KR5]
showed higher cellular uptake of a phosphopeptide as compared to monocyclic peptides (c[KR5]
or c[WR]4). These data indicated that for better cellular uptake of these cyclic peptides, an optimal
balance of positive charge and hydrophobicity is essential for interactions with the cell membrane
and deep penetration into the lipid bilayer [15]. c[WR]5 consists of a balance of hydrophobicity and
positive charges. We hypothesized that this peptide template could be extended into a tricyclic peptide
platform as a multivalent structure for application in drug delivery.
Most of the biological interactions are controlled via multivalent interactions with respect to density,
spacing, complex interaction, and various dynamic effects [25–28]. Thus, it is always challenging
to effectively be amended. Multivalent constructs were prepared using preorganized cyclopeptides
or dendrimers using various methodologies, mainly “click reactions” [2]. Copper-catalyzed “click
reaction” has various advantages, but the introduction of copper species to in vivo systems raises
the concern of potential toxicity [29–31]. Various strategies, including the development of chelating
azides as reagents, are being adopted to reduce the copper-induced toxicity [32]. We have previously
shown that higher cellular uptake of a phosphopeptide in the presence of bicyclic peptide containing
amide linkage c[W5E]-(β-Ala)-c[KR5] than bicyclic peptide (c[W5G]-(triazole)-c[KR5] [22], presumably
due to the more flexibility of the linker between two cyclic peptides containing the amide linker for
generating a proper conformation for effective interaction with the cell membrane.
Thus, to unravel a new multivalent tricyclic peptide as a molecular transporter, herein, we synthesized
a tricyclic peptide based on naturally occurring amino acids using a simpler biocompatible and
biodegradable amidic linkage instead of a triazole formed through click chemistry. The tricyclic peptide
was a trimer of monocyclic peptides containing alternating hydrophobic residues (W) and charged
residues (R) in addition to lysine (K) residues that assist in the generation of an amide linkage through
their side chain amino group. Herein, we report antibacterial activity and molecular transporter
properties of the tricyclic peptide.
2. Materials and Methods
2.1. Materials
Fmoc amino acids, coupling reagents, and amino acid-loaded chlorotrityl resin were obtained
from AAPPTec (Louisville, KY, USA). The solvents and chemical reagents were purchased from
MilliporeSigma (Milwaukee, WI, USA) and used without further purification. Crude peptides were
purified using reverse phase high performance liquid chromatography (RP-HPLC) using Hitachi
L-2455 system (Canby, OR, USA) with a C18 Phenomenex column (Prodigy, 10 µm, 2.1 cm × 25 cm),
at a flow rate of 10 mL/min with the detection at 214 nm using a gradient of 0–100% acetonitrile
(0.1% trifluoracetic acid (TFA)) and water (0.1% TFA) over 60 min. Peptides were characterized for
confirmation of their exact mass using Bruker GT 0264 (Fremont, CA, USA) matrix-assisted laser
desorption/ionization (MALDI) mass spectrometer with α-cyano-4-hydroxycinnamic acid as a matrix
under positive mode. Human breast cancer (MDA-MB-231, HTB-26) cell line was obtained from
American Type Culture Collection (ATCC, Manassas, VA, USA). Cell culture media were obtained from
Fisher Scientific. Bacterial strains: Methicillin-resistant Staphylococcus aureus (MRSA) (Los Angeles
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County (LAC) clone) and E. coli (ATCC 25922) were acquired from the Loss Angeles Public Health
Department (Los Angeles, CA, USA). Pseudomonas aeruginosa (ATCC 27883) and Klebsiella pneumoniae
(ATCC BAA 1705) were obtained from ATCC. The media for bacterial experiments were purchased
from Hardy diagnostic (Santa Maria, CA, USA).
2.2. Chemistry
2.2.1. General Method for the Synthesis of Monocyclic Peptides
In general, all cyclic peptides were synthesized by the Fmoc solid-phase synthesis strategy
followed by cyclization in the solution. H-Arg(Pbf)-2-chlorotrityl resin (1) (1 g, 0.58 mmol, 0.58 meq/g,
100–200 mesh) was swelled in N,N-dimethylformamide (DMF) (50 mL) under nitrogen in a 500 mL
peptide synthesis vessel. After 2 h, DMF was drained out, and a solution of Fmoc-Trp(Boc)-OH
(1.74 mmol, 916.3 mg), 1-[bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate
3-oxide (HBTU) (1.74 mmol, 660 mg), and N,N-diisopropylethylamine (DIPEA) (3.48 mmol, 606 µL)
in DMF (20 mL) was added to the resin. The resin was agitated under nitrogen for 30 min for
coupling the first amino acid. After 30 min, the reaction mixture was drained and washed with
DMF (10 mL × 3 times). A solution (20 mL) of 20% piperidine in DMF (v/v) was added to remove
the N-terminal Fmoc group with the agitation of peptidyl resin for 20 min two times followed by
washing with DMF (10 mL × 3 times). In a similar way, the subsequent Fmoc-protected amino acids
were coupled based on the required sequence of the linear peptides. Once the linear protected peptide
was assembled on the peptidyl resin, the side-chain-protected peptide was cleaved from the resin for
N to C terminal cyclization. The peptidyl resin was stirred with freshly prepared cleavage cocktail
containing trifluoroethanol (TFE)/acetic acid/dichloromethane (DCM) (2:1:7, v/v/v, 50 mL) for 2 h.
The resin was filtered off, and the supernatant was evaporated to dryness to get side chain-protected
linear peptides (2, 8, 13). The side-chain-protected peptide (300 mg) was taken in 2 L round bottom
flask under nitrogen. DMF and DCM (2:1, v/v, 1.2 L) were added to the mixture. A solution of
1-hydroxyazabenzotriazole (HOAt) (236.8 mg) in DMF and N,N’-diisopropylcarbodiimide (DIC)
(269.4 µL) were added. The reaction was stirred for 24 h under nitrogen. The solvents were
evaporated under vacuum, and side chains were deprotected by agitation with freshly prepared
cleavage cocktail containing TFA/thioanisole/anisole/1,2-ethanedithiol (EDT) (90:5:2:3, v/v/v/v, 10 mL) for
2 h. The crude peptides were precipitated by the addition of cold diethyl ether (Et2O) and centrifugation.
Crude peptides were purified with RP-HPLC. The peptides were separated by eluting the crude
peptides at 10.0 mL/min using a gradient of 0–100% acetonitrile (0.1% TFA) and water (0.1% TFA) over
60 min and then characterized by MALDI TOF mass spectroscopy. The desired fractions were pooled
and lyophilized to yield cyclic peptides. MALDI spectra of intermediate and synthesized compounds
and selected analytical HPLC have been provided in the Supplementary Materials.
2.2.2. Synthesis of Monocyclic Cyclic Peptides Containing Free Amino or Free Carboxylic Acid or Both
[D-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-K(Dde)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)] (4) containing free
carboxylic acid.
The side-chain-protected linear peptide (NH2-D(OAll)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-K(Dde)-
W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-tritryl resin) was assembled on H-Arg(Pbf)-2-chlorotrityl resin (1, 1 g,
0.58 mmol) using building blocks of Fmoc-protected amino acids, such as Fmoc-Trp(Boc)-OH (916.3 mg),
Fmoc-Arg(Pbf)-OH (1128 mg), Fmoc-Lys(Dde)-OH (926.7 mg), and Fmoc-Asp-(OAll)-OH (687.9 mg),
followed by cleavage from the solid support to afford 460 mg (24%) of the linear side-chain-protected
peptide (NH2-D(OAll)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-K(Dde)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-COOH)
(2). MALDI-TOF (m/z) for 2, [C91H124N27O15]: calcd, 1834.9765; found, 1835.1590 [M + H]+.
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Compound 2 underwent cyclization to obtain side-chain-protected peptide [D(OAll)-W(Boc)-
R(Pbf)-W(Boc)-R(Pbf)-K(Dde)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)] (3) using general peptide synthesis
method explained in Section 2.2.1. Cyclic peptide 3, 418 mg (91%) was dried for 24 h before using for
the subsequent reaction. MALDI-TOF (m/z) for 3, [C91H121N27O14]: calcd, 1815.9586; found, 1817.9611
[M + 2]+.
To obtain compound 4, the protected cyclic peptide 3 (200 mg) was taken in a dry round bottle
flask fitted with a rubber septum and under the inert condition with N2. A solution containing
Pd(PPh3)4 (2.01 g, 0.00174 mmol, 3.0 equiv) and CHCl3:AcOH:N-methyl morpholine (37:2:1, v/v/v,
25 mL) was added, and the mixture was stirred for 2 h followed by evaporation of solution under
rotatory evaporator. A solution of 0.5% DIPEA and sodium diethyldithiocarbamate (0.5% w/w) in
DMF was added to the evaporated residue to remove the catalyst. The solvent was evaporated to
remove all the solvents. The crude mixture was washed with water (8–10 mL) to get rid of all side
products following with centrifugation (1200 rpm, 3 × 5 min). After centrifuging the crude peptide,
it was dried overnight to obtain the protected cyclic peptide 4 (136 mg, 69%). MALDI-TOF (m/z) for 4,
[C88H117N27O14]: calcd, 1775.9273; found, 1777.8700 [M + 2]+.
[D(OAll)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-K-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)] (5) containing free
amino group.
To obtain the Dde-deprotected cyclic peptide 5, a solution of 2% hydrazine monohydrate solution
in DMF (50 mL) with 7.8 mL of allyl alcohol was added to the peptide 3 (200 mg) and stirred at room
temperature for 2 h. The reactant mixture was evaporated under vacuum to dryness and washed with
cold water. The obtained solid was dried to yield side-chain-protected cyclic peptide 5 (124 mg, 65%).
MALDI-TOF (m/z) for 5, [C81H111N27O12]: calcd, 1653.8895; found, 1654.5044 [M + H]+.
Deprotected cyclic peptide [DWRWRKWRWR] (7) containing free amino and free carboxylic acid.
Peptide 4 was deprotected using 2% hydrazine monohydrate in DMF to afford protected cyclic
peptide [DW(Boc)R(Pbf)W(Boc)R(Pbf)KW(Boc)R(Pbf)W(Boc)R(Pbf)] (6). Alternatively, peptide 5 was
deprotected using Pd(PPh3)4 and CHCl3:AcOH:N-methylmorpholine as mentioned above to obtain 6
(94 mg, ~72% + 90 mg, 74%). Finally, peptide 6 was completely deprotected to remove Pbf and Boc groups
by stirring with freshly prepared cleavage cocktail containing TFA/thioanisole/anisole/1,2-ethanedithiol
(EDT) (90:5:2:3, v/v/v/v, 10 mL) for 2 h to yield fully deprotected cyclic peptide [DWRWRKWRWR] 7.
MALDI-TOF (m/z) for 7, [C78H105N27O12]: calcd, 1611.8436; found, 1613.2794 [M + H]+.
2.2.3. Synthesis of Diamine Cyclic Peptide [KWRWRKWRWR] (10) and Diacid Cyclic Peptide
[K(COCH2CH2COOH)WRWRK(COCH2CH2COOH)WRWR] (12)
Using the general protocol mentioned in Section 2.2.1, the monocyclic peptide was assembled
on H-Arg(Pbf)-2-chlorotrityl resin (1, 1 g, 0.58 mmol) using building blocks of Fmoc-protected
amino acids, such as Fmoc-Trp(Boc)-OH (916.3 mg), Fmoc-Arg(Pbf)-OH (1128 mg), and Fmoc-Lys
(Dde)-OH (926.7 mg), based on the sequence of amino acids in the diamine cyclic peptide 10 followed
by cleavage from solid support to afford side-chain-protected linear peptide NH2-K(Dde)-W(Boc)-
R(Pbf)-W(Boc)-R(Pbf)-K(Dde)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-COOH (8, 432 mg, 22%). MALDI-TOF
(m/z) for 8, [C100H138N28O15]: calcd, 1971.0896; found, 1972.3850 [M + H]+.
Compound 8 was cyclized and deprotected for Dde group using HOAt/DIC and 2% hydrazine
in DMF, respectively, to provide side-chain-protected cyclic peptide [K-W(Boc)-R(Pbf)-W(Boc)-
R(Pbf)-K-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)] (9, 321 mg, 89%). Cyclic peptide 9 was divided into two parts
(120 mg and 200 mg).
To the first part, a freshly prepared cleavage cocktail containing TFA/thioanisole/anisole/
1,2-ethanedithiol (EDT) (90:5:2:3, v/v/v/v, 10 mL) was added. The mixture was stirred at room temperature
for 2 h to fully deprotect side chain protecting groups and afford 10. MALDI-TOF (m/z) for 10,
[C80H112N28O10]: calcd, 1624.9116; found, 1626.4005 [M + H]+.
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To the second part of peptide 9 (200 mg) taken in DCM (25 mL), triethylamine (242.5 µL)
was added at 0 ◦C followed by the addition of succinic anhydride (174.1 mg). The mixture was
stirred at room temperature for 2 h. DCM was evaporated under vacuum, and the solid residue was
washed with water and dried to afford crude product [K(COCH2CH2COOH)-W(Boc)-R(Pbf)-W(Boc)-
R(Pbf)-K(COCH2CH2COOH)W(Boc)R(Pbf)W(Boc)R(Pbf)] (11, 210 mg, 98%). After drying the crude
product, the side chain-protecting groups were deprotected by stirring peptide 11 with a freshly
prepared cleavage cocktail containing TFA/thioanisole/anisole/1,2-ethanedithiol (EDT) (90:5:2:3, v/v/v/v,
10 mL) at room temperature for 2 h. The peptides were precipitated and centrifuged to obtain a fully
deprotected diacid of cyclic peptide [K(COCH2CH2COOH)-WRWR-K(COCH2CH2COOH)WRWR]
(12). MALDI-TOF (m/z) for [K(COCH2CH2COOH)-WRWR-K(COCH2CH2COOH)WRWR] (12),
[C88H120N28O16]: calcd, 1824.9437; found, 1826.3790 [M + H]+.
2.2.4. Synthesis of a Monoamine Cyclic Peptide [RWRWKRWRW] (16) and a Mono Carboxylic Acid
Cyclic Peptide [K(COCH2CH2COOH)-WRWRWRWR] (18)
Using the general protocol mentioned in Section 2.2.1, the monocyclic peptide was assembled on
H-Arg(Pbf)-2-chlorotrityl resin (1, 1 g, 0.58 mmol) using building blocks of amino acids, Fmoc-Trp
(Boc)-OH (916.3 mg), Fmoc-Arg(Pbf)-OH (1128 mg), and Fmoc-Lys(Dde)-OH (926.7 mg) based on
the sequence of peptide 16. The linear assembled peptide (13, 428 mg, 24%) was cleaved from the
solid support and cyclized as mentioned in the general protocol to obtain crude cyclized peptide
[K(Dde)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)] (14, 377 mg, 88%).
To peptide 14 (300 mg), a solution of 2% hydrazine monohydrate in DMF (50 mL) was added
to deprotect Dde group. The solution was stirred for 2 h, and the reaction mixture was evaporated
under vacuum to dryness and washed with cold water. The solid obtained was dried to obtain
side-chain-protected cyclic peptide [K-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)]
(15, 354 mg, 93%). Peptide 15 was divided into two parts (154 mg and 200 mg).
To the first part of peptide 15 (154 mg), a freshly prepared cleavage cocktail containing
TFA/thioanisole/anisole/1,2-ethanedithiol (EDT) (90:5:2:3, v/v/v/v, 10 mL) was added and stirred at
room temperature for 2 h to deprotect side chain-protecting group. The second part of peptide 15
(200 mg) was dissolved in DCM (25 mL) and kept at 0 ◦C. Triethylamine (121.3 µL) was added
to the solution of succinic anhydride (87.1 mg) in DCM was added slowly to the reaction mixture
at 0 ◦C. The reaction mixture was stirred at room temperature for 2 h. DCM was evaporated
under vacuum and the residue was washed with water and dried to obtain crude product
[K(COCH2CH2COOH)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)-W(Boc)-R(Pbf)] (17, 196 mg,
98%). The side chain protecting group of peptide 17 was deprotected by reacting with freshly prepared
cleavage cocktail containing TFA/thioanisole/anisole/1,2-ethanedithiol (EDT) (90:5:2:3, v/v/v/v, 10 mL) at
room temperature for 2 h.
The cleaved peptides were precipitated and centrifuged to obtain fully deprotected cyclic peptides
containing monoamine [KWRWRWRWR] (16) and monocarboxylic acid [K(COCH2CH2COOH)-
WRWRWRWR] (18). MALDI-TOF (m/z) for [KWRWRWRWR] (16), [C74H101N26O9]: calcd, 1496.8167;
found, 1497.7751 [M + 1]+. MALDI-TOF (m/z) for [K(COCH2CH2COOH)-WRWRWRWR] (18),
[C78H106N26O12]: calcd, 1596.8237; found, 1598.7387 [M + 2]+.
2.2.5. Synthesis of Tricyclic Peptide 20
To a round bottom flask, the side-chain-protected cyclic peptides, diamine peptide (9) (10.0 mg,
3.29 × 10−6 mol) and monocarboxylic acid peptide (17) (39.6 mg, 13.18 × 10−6 mol) were added in 10 mL
anhydrous DMF under stirring and inert condition using septum and purge of N2. The reaction mixture
was kept at 0 ◦C followed by slow addition of N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC.HCl) (3.1 mg, 16.47 mmol) and 4-dimethyl aminopyridine (DMAP) (0.2 mg,
1.65 mmol) with stirring for 1 h. The reaction mixture was allowed to reach room temperature and
stirred for 24 h. The completion of the reaction was monitored by mass analysis of aliquot after complete
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deprotection of the reaction mixture using MALDI. Once the reaction was completed, the reaction
mixture was evaporated to the dryness to yield peptide 19, 24 mg, 80%, and the residue was treated
with the freshly prepared cleavage cocktail containing TFA/thioanisole/anisole/1,2-ethanedithiol (EDT)
(90:5:2:3, v/v/v/v, 10 mL) at room temperature for 2 h. The peptide was precipitated and centrifuged to
obtain fully deprotected tricyclic peptide 20, crude 10 mg, 78% that was purified by HPLC as described
above to get pure compound 6 mg. MALDI-TOF (m/z) for 20, [C236H316N80O32]: calcd, 4782.5559;
found, 4782.1199 [M]+.
2.3. Bioassay
2.3.1. Antibacterial Assay
The selected strains of bacteria, MRSA (Los Angeles County (LAC) clone), E. coli (ATCC 25922),
Pseudomonas aeruginosa (ATCC 27883), and Klebsiella pneumoniae (ATCC BAA 1705) were cultured
according to the guidelines of the Clinical Laboratory Standards Institute (CLSI) guidelines. MIC values
were determined using microbroth dilution assay. Tricyclic peptide 20 was used to evaluate antibacterial
activity in comparison to positive controls, such as Meropenem for Gram-negative bacteria and c[R4W4]
for Gram-positive bacteria. Bacterial strains were inoculated into LB (5 mL) and shaken in an orbital
shaker at 175 rpm overnight at 37 ◦C. The cultured suspension was immediately diluted to get turbidity
of 0.5 McFarland (1.5 × 108 bacterial cell CFU/mL) using normal saline. The test compounds (tricyclic
peptide 20, Meropenem, and c[R4W4]) were dissolved in 5% dimethyl sulfoxide (DMSO) to generate
256 µg/mL solutions. 200 µL of tricyclic peptide 20, and controls were added to the first column of the
96 well plates, and a twofold serial dilution was performed with the addition of 100 µL of bacterial
culture media to the other wells. The corresponding control DMSO 5% alone without the compound
in similar concentration exhibited no antibacterial activity when diluted in the final concentration.
Bacterial solution (100 µL) was added to all the wells and incubated statically at 37 ◦C overnight.
The minimum concentration at which bacterial growth was not visible to eyes were reported as MICs
and experiments were performed in triplicate.
2.3.2. Cellular Cytotoxicity Assay
Human breast cancer (MDA-MB-231) cell line was grown on 75 cm2 cell culture flasks with
Dulbecco’s modified eagle’s medium (DMEM) medium, supplemented with 10% fetal bovine serum
(FBS), and 1% penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in
0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 ◦C. CellTiter 96® Aqueous (Promega,
Madison, WI, USA) one solution cell proliferation assay (MTS) was utilized to evaluate MDA-MB-231
cell viability. Cells were seeded into 96-well plate (104 cells/100 µL) in complete media and incubated
overnight at 37 ◦C with 5% CO2. Different concentrations (0−300 µM) of the peptide solution (10 µL)
were added to wells to make the final concentrations of the peptide (0−30 µM). The cells were incubated
again (37 ◦C, 5% CO2) for 24 h, then MTS reagent (20 µL) was added to each well followed by incubation
for 2 h under the same condition. The absorbance of the resulting solution was evaluated at 490 nm
using a microplate reader to detect the live cells. Cells without peptide were considered as a control.
DMSO (30% v/v) was used as a positive control. The compound was used in aqueous solution. All the
tests were performed in triplicate.
2.3.3. Cellular Uptake of Fluorescence-Labeled Phosphopeptide (F’-GpYEEI) and Anti-HIV Drugs
(Lamivudine (F’-3TC), Emtricitabine (F’-FTC), and Stavudine (F’-d4T)
Human breast cancer cells (MDA-MB-231) were grown in 6-well plates (2 × 105 cells/well) in
DMEM overnight. Then different fluorescence-labeled molecules (F’-3TC, F’-FTC, and F’-d4T) at
5 µM or F’-GpYEEI (5 µM) in the presence or absence of the tricyclic peptide 20 (25 µM) in opti-MEM
were added, where F’ represents carboxyfluorescein and pY represents the phosphotyrosine amino
acid). F’-GpYEEI, F’-3TC, F’-FTC, or F’-dT4 and cyclic peptide 20 were premixed in opti-MEM at
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room temperature for 30 min. The cells were incubated with the premixed solution for 3 h at 37 ◦C.
5-(6) carboxyfluorescein (FAM or F’) was used as a negative control. After 3 h incubation, the media
containing peptide was removed. The cells were washed twice with PBS, followed by digestion with
0.25% trypsin/0.53 mM EDTA for 5 min to remove any false surface binding. Then PBS was added to
wash the cells. The cells were centrifuged (600 rpm, 5 min) to collect the pellet. Finally, the obtained
pellet was resuspended in buffer designated for flow cytometry and analyzed by flow cytometry
(FACSCalibur: Becton, Dickinson & Co. (Franklin Lakes, NJ, USA)) using FITC channel and CellQuest
software. The data depicted in the results are determined by using the mean fluorescence signal for
10,000 cells collected. Flow cytometry analysis was performed in triplicate.
2.3.4. siRNA Delivery
Peptide/siRNA complexes were made by simple mixing of fluorescence-labeled siRNA
(FAM-siRNA, Qiagen, Cat no 1027292) and peptides in different N/P ratios. First, FAM-siRNA
was added to 150 mM NaCl solution. Tricyclic peptide 20 was dissolved in sterilized water to make a
stock concentration of 1 mM. The peptide solution was mixed gently with siRNA/saline mixture at
different N/P ratios. Then the resulting mixtures were allowed to stand for 30 min at room temperature
for complete complex formation. N/P ratio was determined by the following equation:
N/P = (Number of moles for peptide × Number of Nitrogens)/(Number of moles for siRNA × 48)
where 48 represents the average number of phosphates in each siRNA molecule.
Cells were seeded in 24-well plates at ~200,000 cells/mL. After overnight seeding, peptide/siRNA
complexes were added. Peptide/siRNA complexes were made with peptide: siRNA N/P ratios of 10,
20, and 40, respectively. After 24 h of incubation at 37 ◦C, the cells were washed with hanks balanced
salt solutions (HBBS), trypsinized, and fixed with 3.7% formaldehyde solution. Quantification of
siRNA uptake was performed by Flow cytometer (BD-FACSVerse, BD Biosciences; San Jose, CA, USA)
using the FITC channel to evaluate intracellular fluorescence signal. The mean fluorescence of cells in
the selected cell population was determined. The results were calibrated by gating with the control
cells (i.e., “No Treatment”) group in such a way that the auto-fluorescent cells became ~1% of the total
cell population.
2.3.5. Statistical Analyses
To evaluate the statistical significance of the results, ANOVA test was carried out using a single
factor in MS Excel 2016. In case of cytotoxicity assay, cells without treatment were considered as the
control and compared with the treated groups. For cellular uptake studies, only drug treated cells
were considered as the control and compared with drug/carrier mixture. p-value less than 0.05 was
considered as statistically significant and included in the Figures.
3. Results & Discussion
3.1. Chemistry
For the synthesis of click-free tricyclic peptide, we designed and followed various strategies.
In the first approach, we started with the synthesis of two cyclic peptides that contained one free
carboxylic acid and one free amino group to perform intermolecular conjugation between them or to
oligomerize a cyclic peptide containing a free amino group and a free carboxylic acid [33]. Scheme 1
depicts the synthesis of monocyclic peptides and efforts to perform conjugation to develop bicyclic or
tricyclic peptides. The exterior square bracket [] is used to represent cyclic peptides obtained through
N to C terminal cyclization; however, parentheses () represent linear peptides.
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i i t .
The side-chain- rotected linear pe tide (2) was assembled on 2-chlorotrityl resin starting from
H-Arg(Pbf)-2-chlorotrityl resi (1) using Fmoc/tBu solid-phase peptide synthesis strategy followed
by cleavage of the protected peptide from the resin using cleavage cocktail (TFE:DCM:AcOH) at the
room temperature to afford 2. Linear protected peptide 2 was cyclized under dilute condition using
HOAt and DIC to yield protected peptide 3 acc rding t the previously reported procedure [16].
Cyclic peptide 3 contains an orthogon l protecting group of lysine known as Dde (4,4-dimethyl-
2,6-dioxocyclohex-1-ylidene)ethyl) at the epsilon amino group of the lysine side chain. The Dde was
selectively deprotected in the presence of 2% ydrazine monohydrate solution in DMF to generate a
c clic peptide containing a free NH2 group in (5).
While to get the cyclic pepti e with the free carboxylic acid, th orthogonal protecti g group of
allyl est r of aspartic acid (OAll) in cyclic peptide 3 was selectively deprotected under a mild c ndition
and Pd(0) cat lyst to afford (4). Cyclic peptides 4 and 5 were reacted in the presence of different
coupling reagents, but the conjugation reaction was not successful, possibly due t the steric hindrance
of bulky groups pr sent in both peptides.
Alt rnatively, the cyclic peptides 4 nd 5 were further deprotected for removal of orthogonal
rotecting groups using 2% hydrazine monohydrate solution in DMF and tetrakis(triphenylphosphine)
palladium(0) under mild condition, respectively, to afford yclic peptide 6, whi h was completely
deprote ted to remove Pbf and Boc groups to afford bifunctional cyclic peptide [DWRWRKWRWR]
(7) containing both free amino and carboxylic acid groups as new bifunctional cyclic peptide.
The conjugation of the cyclic peptide with itself failed to generate any dicyclic peptide.
In the second approach, we attempted to explore the enzymatic condensation polymerization
between a diamine functional group-containing cyclic peptide 10 and a diacid functional group-
containing cyclic peptide 12 using Novazyme-435, a lipase usually used for polyamide or polyester
synthesis [34,35]. Thus, we included two lysine amino acid residues in the sequence of the cyclic
peptide to get diamine residue, which could also be further modified from intermediate protected
peptide 9 to diacid 12 after reacting to succinic anhydride. Scheme 2 depicts the synthesis of cyclic
peptide building blocks (10 and 12).
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Scheme 2. Synthesis of cyclic i i i fr a ino or two fr e carboxylic acids.
The synt esis was started with the synthesis of side-chain-protected linear peptid 8 f ll wed by
cyclization and deprotection of Dde g oups to yield side-chain-protected cyclic peptid 9. Peptide
9 was divided into two parts, and one part was completel deprotected in the side chains o afford
cyclic peptide containing diamine function l group [KWRWRKWRWR] 10. The second part of cyclic
peptide 9 was reacted with succinic anhydride in anhy rous condition to obtain a di cid functionalized
side-chain-protected peptide 11. The complete deprotection afforded iacid containing two free
carboxylic acids in the cyclic peptide (12).
The enzy atic synthesis of multivalent cyclic peptide or polymerization of peptide 9 with peptide
11 and peptide 10 with peptide 12 were attempted using Novazyme-435 as a catalyst at 50 ◦C, 60 ◦C,
and 70 ◦C without success, presumably due to lack of access of the cyclic peptides to the catalytic triad
of the enzyme because of the bulky size.
In the third approach, we designed and synthesized cyclic peptides with a free monoamine
functional group (16) and free monocarboxylic acid functional group (18) as shown in Scheme 3.
The protected linear peptide (13) was synthesized, followed by cyclization to afford cyclic peptide
14. The Dde group was removed using hydrazine to afford protected peptide 15, which was divided
into two parts. The first part underwent complete deprotection to yield mono amine-containing
cyclic peptide [KWRWRWRWR] (16). The second part was functionalized by reacting with succinic
anhydride to afford mono acid-containing cyclic peptide 17. The complete deprotection of peptide 17
afforded mono carboxylic acid-containing cyclic peptide 18.
Finally, the conjugation of monocarboxylic containing cyclic peptide 17 was performed with
diamine cyclic peptide 9 using EDC/DMAP as coupling reagents under an anhydrous condition for
24 h to obtain side-chain-protected tricyclic peptide 19 (Scheme 4). The complete deprotection of side
chains in the tricyclic peptide 19 yielded multivalent tricyclic peptide 20. The purity of the peptide
was confirmed by analytical HPLC.
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3.2. Biological Activity 
The cytotoxicity of tricyclic peptide 20 was determined by the MTS assay against breast cancer 
cell lines (MDA-MB-231). Tricyclic peptide 20 showed more than 97% cell viability in MDA-MB-231 
cell lines up to a concentration of 25 µM, which slightly decreased to 92% at 30 µM (Figure 2). Thus, 
further cell-based assays were conducted at 25 µM. 
. t i f t i li ti f i li ti .
The analysis of our synthetic effort reflects that conjugation or coupling of a bifunctional cyclic
peptide containing protected side chains or unprotected cyclic peptide (first approach) was not
successful due to the steric hindrance associated ith the side chains of tryptophan residues in the
cyclic peptide. Moreover, steric hindrance may be due to the use of carboxylic acid for conjugation
from the aspartic acid side chain, which was in the proximity of the backbone of the cyclic peptide.
Therefore, we tried to use a lipase family enzyme named Novazyme-435 to facilitate conjugation and
or polymerization of diamine or diacids containing protected or unprotected side chains in the cyclic
peptides. However, the MALDI analysis did not show any conjugation. Novazyme-435 was reported
to be used in the synthesis of polyamide or polyester from small molecules but did not produce
any success with the case of cyclic peptides during our synthesis. Finally, the use of diamine cyclic
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peptide from the second approach and monofunctionalized carboxylic acid with a succinate linker was
examined (third approach) using EDC and DMAP as classical peptide coupling reagents. The third
approach afforded the tricyclic peptide, possibly due to the availability of four extra carbon atoms as a
linker in the lysine side chain, which enhanced activation of the COOH group followed by conjugation
to the diamine of the cyclic peptide.
3.2. Biological Activity
The cytotoxicity of tricyclic peptide 20 was determined by the MTS assay against breast cancer
cell lines (MDA-MB-231). Tricyclic peptide 20 showed more than 97% cell viability in MDA-MB-231
cell lines up to a concentration of 25 µM, which slightly decreased to 92% at 30 µM (Figure 2). Thus,
further cell-based assays were conducted at 25 µM.
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Figure 2. Cytotoxicity of tricyclic peptide 20 in MDA-MB-231 cells (if p < 0.01 then **). DMSO (35% v/v)
was used as the positive control. The compound was used in the aqueous solution.
Phosphopeptides contain negatively-charged phosphate moieties, which restrict the peptides to
cross the cellular me branes [36,37]. The olecular transport of these valuable probes into cellular
systems presents a great dvantage for t t of phosphoprotein-protein interactions as well as
protein phos horylation a d dephosphorylation. The potential of tricycli pe tide 20 for the d livery
of fluorescently lab led (F’)-Gly-(pTyr)-Glu-Glu-Ile (F’-GpYEEI) was analyzed with flow cytometry.
The percentage of fluorescently positive cells exceeded 98%, while non-treated cells or phosphopeptide
alone were less than 0.6%. In terms of mean fluorescence, the cellular uptake was enhanced at least
by 18 times in the presence of tricyclic peptide 20, suggesting the role of the latter as a successful
delivery tool (Figure 3). The delivery efficiency of the tricyclic peptide was compared with monocyclic
peptide [WR]5. However, the newly developed tricyclic peptide was found to be less efficient than the
monomer. This could be due to the steric hindrance of the tricyclic peptide, which could restrict its
binding affinity toward the phosphopeptide.
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To study the application of the newly synthesized tricyclic peptide 20 as a molecular transporter,
the cellular uptake of three different fluorescently labeled anti-HIV drugs, lamivudine (3TC), emtricitabine
(FTC), stavudine (d4T) (F′-3TC, F′-FTC and F′-d4T) was examined in the presence and absence of the
tricyclic peptide 20 using MDA-MB-231 cell line (Figure 4). After 4 h of inc bation at 37 ◦C, the cells
were washed with PBS followed by tre tment with trypsin. Th cellular uptake was monitored with
flow cytometry. The data demonstrated exhibited significantly greater fluorescence signals in the cells
incubated with the F′-3TC and F′-FTC-loaded with the tricyclic peptide 20, compared to those treated
with the fluorescently-label d compounds alone, indicating that the uptak of these two compounds
is promoted by the tricyclic peptide. For instance, the cellular internalization in t e presence of the
peptide was approximately nine times higher for F′-3TC and almost twelve times higher for F′-FTC,
which is significantly higher than the previously reported monocyclic peptide [WR]5 [13]. Interestingly,
there was no significant incr ase in the mean fluorescence of the cells in the case of F′-d4T (less than
twofold difference), although the percentage of fluorescently positive cells exceeded 98%. The lower
cellular uptake of d4T as compared to 3TC or FTC could be speculated based on interactions of
the pyrimidine ring of drugs with the phospholipid bilayer and tricyclic peptide 20. This may be
attributed to the presence of the amino group in the pyrimidine ring of 3TC and FTC as compared to
d4T. More interactions possibly occur with the tricyclic peptide; therefore higher cellular uptake was
achieved for FTC and 3TC.
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siRNA has been shown as an alternative therapeutic approach in cancer treatment. One major
obstacle for this approach has been the poor cellular internalization of the double-stranded RNA,
which has anionic and hydrophilic character [38]. Different strategies have been used for siRNA delivery,
including the use of synthesized cyclic peptides after complex formation with fluorescently labeled
siRNA. Tricyclic peptide 20 showed 3.3-fold improvements in siRNA internalization compared to
siRNA alone at the lowest peptide:siRNA ratio N/P 10, which progressively decreased with an increase
in the N/P ratio (Figure 5) in the MDA-MBA-231 cell line. At a 20:1 ratio, the cellular internalization
of siRNA decreased, and at 40:1 ratio, there was no major difference in siRNA uptake compared to
free siRNA. Both of them did not show any statistical difference to the control group (NT). The result
suggests that at a lower N/P ratio, the peptide shows appreciable efficiency in siRNA delivery; however,
at higher N/P ratio, the efficiency is decreased. This may be attributed to the possible intermolecular
hydrogen bonding among the arginine residues at high concentration, which reduces the available
cationic charges in the peptide; thus, loading of anionic siRNA on peptides is decreased.
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As a part of the innate immune system, peptides possess a broad-spectrum antimicrobial activity [39–41].
Cyclic peptides, in particular, are considered as an emerging class of antimicrobial peptides against
antibiotic-resistant pathogens [42,43]. c[R4W4] is a cyclic amphiphilic peptide exhibited potent antibacterial
activity against MRSA (MIC 4 µg/mL) and E. coli (MIC 16 µg/mL) and showed improved antibacterial
activity hen co-administered w th tetrac cline [23,24]. The tructure-antibacterial activity of a series
of c[R4W4] peptides reve led the requirement of R and W amino acids [24]. Thus, we decided to
perform the antibacterial activity of tricyclic peptide 20. The tricyclic peptide 20 exhibited modest
antibacterial activity against MRSA, Pseudomonas aeruginosa, Klebsiella pneumoniae, and E. Coli with MIC
values in the range of 64–128 µg/mL, which was significantly lower than c[R4W4] (Table 1). These data
were not unexpected since the peptide contained alternative R and W residues rather than blocks of
hydrophobic and positively charged residues on opposite sides, like c[R4W4], required for a more
amphiphilic property to generate potent antibacterial activity.
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Table 1. Antibacterial activity of Tricyclic peptide 20.
Compound Name
MIC (µg/mL) #
MRSA
(LAC Clone)
Klebsiella pneumoniae
(ATCC BAA 1705)
Pseudomonas aeruginosa
(ATCC 27883)
E. coli
ATCC 25922)
Meropenem 4 32 1 8
c[R4W4] 4 32 64 16
Tricyclic Peptide 20 64 128 128 64
# Experiments were performed in triplicate.
4. Conclusions
We designed and synthesized tricyclic [(WR)4]3 after two unsuccessful synthetic strategies using
Fmoc/tBu solid-phase synthesis. In the first approach, the intermolecular coupling of monfunctional
cyclic peptides did not produce conjugated peptide, while in the second approach, the intermolecular
coupling of diamine or dicarboxylic acid failed to produce a bicyclic peptide. However, by reacting
protected diamine cyclic peptide 9 with a mono carboxylic-succinate-cyclic peptide 17, tricyclic peptide
20 was synthesized. The evaluation of the antibacterial activity of tricyclic peptide showed modest
activity against MRSA, Pseudomonas aeruginosa, Klebsiella pneumoniae, and E. coli with MIC values
of 64–128 µg/mL. Tricyclic peptide 20 was also evaluated for molecular transporter activity after
it was found to be nontoxic up to 30 µM in the MDA-MB-231. Tricyclic peptide 20 enhanced the
cellular uptake of phosphopeptide F’-GpYEEI by 18-fold as compared to the uptake F’-GpYEEI alone.
Similarly, the uptake of antiviral drugs (d4T, 3TC, and FTC) was enhanced in the presence of tricyclic
peptide 20 by 1.9–12-fold as compared to the drug alone. Tricyclic peptide 20 also internalized a
fluorescent-labeled siRNA into the MDA-MB-231 cells by 3.3-fold at N/P ratio of 10 as compared to
siRNA alone. Further optimization in the design and application of tricyclic peptide will be required
to access the full potential of these multivalent compounds in the biological system. Our data also
reflect the potential of the tricyclic or polycyclic peptides in the area of drug delivery.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/9/842/s1,
MALDI spectra of intermediate and synthesized compounds. Figure S1: Preparatory RP-HPLC profile of tricyclic
peptide 20, Figure S2: Analytical RP-HPLC profile of tricyclic peptide 20, Figure S3: Analytical RP-HPLC profile of
peptide 7, Figure S4: Analytical RP-HPLC profile of peptide 10, Figure S5: Analytical RP-HPLC profile of peptide
16, Figure S6: Analytical RP-HPLC profile of peptide 18, Figure S7: Analytical RP-HPLC profile of crude peptide 12.
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